{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:45:01Z","timestamp":1794411901696,"version":"4.9.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioactive Materials"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.bioactmat.2024.12.029","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T09:30:37Z","timestamp":1736328637000},"page":"516-530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Cancer vaccine designed from homologous ferritin-based fusion protein with enhanced DC-T cell crosstalk for durable adaptive immunity against tumors"],"prefix":"10.1016","volume":"46","author":[{"given":"Jun","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sichen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8122-8450","authenticated-orcid":false,"given":"Jinghua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioactmat.2024.12.029_bib1","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1172\/JCI83871","article-title":"Cancer immunotherapy: harnessing the immune system to battle cancer","volume":"125","author":"Yang","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nrclinonc.2018.27","article-title":"Cancer immunotherapy and the value of cure","volume":"15","author":"Del Paggio","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib3","doi-asserted-by":"crossref","first-page":"1814-.e1","DOI":"10.1016\/j.cell.2023.02.039","article-title":"Advances in cancer immunotherapies","volume":"186","author":"Dagher","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.bioactmat.2024.12.029_bib4","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3390\/vaccines10050816","article-title":"Harnessing the immune system with cancer vaccines: from prevention to therapeutics","volume":"10","author":"Le","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.bioactmat.2024.12.029_bib5","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioactmat.2024.12.029_bib6","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41578-019-0108-1","article-title":"Cancer nanomedicine for combination cancer immunotherapy","volume":"4","author":"Nam","year":"2019","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib7","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ccell.2022.05.015","article-title":"Cancer vaccines","volume":"40","author":"Schiller","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioactmat.2024.12.029_bib8","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13025","article-title":"Peptide-based therapeutic cancer vaccine: current trends in clinical application","volume":"54","author":"Liu","year":"2021","journal-title":"Cell Prolif."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib9","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1511506","article-title":"Trial watch: peptide-based vaccines in anticancer therapy","volume":"7","author":"Bezu","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.bioactmat.2024.12.029_bib10","article-title":"Peptide delivery systems for cancer vaccines","volume":"1","author":"He","year":"2018","journal-title":"Adv. Ther."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/cells12172159","article-title":"Cancer vaccine therapeutics: limitations and effectiveness-A literature review","volume":"12","author":"Kaczmarek","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.bioactmat.2024.12.029_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110721","article-title":"Improving the efficacy of peptide vaccines in cancer immunotherapy","volume":"123","author":"Zahedipour","year":"2023","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1146\/annurev-chembioeng-060718-030347","article-title":"Protein and peptide biomaterials for engineered subunit vaccines and immunotherapeutic applications","volume":"10","author":"Tsoras","year":"2019","journal-title":"Annu. Rev. Chem. Biomol. Eng."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib14","doi-asserted-by":"crossref","first-page":"19509","DOI":"10.1021\/acsnano.2c09708","article-title":"Sulfonium-driven neoantigen-released DNA nanodevice as a precise vaccine for tumor immunotherapy and prevention","volume":"16","author":"Zhang","year":"2022","journal-title":"ACS Nano"},{"issue":"731\u20134","key":"10.1016\/j.bioactmat.2024.12.029_bib15","first-page":"871","article-title":"Aluminium-adjuvanted vaccines--a review of the current state of knowledge","volume":"69","author":"Go\u0142o\u015b","year":"2015","journal-title":"Przegl. Epidemiol."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib16","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.3390\/pharmaceutics15071884","article-title":"Aluminum Adjuvants-'Back to the future'","volume":"15","author":"Laera","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioactmat.2024.12.029_bib17","series-title":"MF59 Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines","author":"Ott","year":"1995"},{"key":"10.1016\/j.bioactmat.2024.12.029_bib18","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1586\/erv.11.192","article-title":"Development and evaluation of AS03, an Adjuvant System containing \u03b1-tocopherol and squalene in an oil-in-water emulsion","volume":"11","author":"Gar\u00e7on","year":"2012","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.bioactmat.2024.12.029_bib19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1006\/cimm.1999.1572","article-title":"Immunostimulatory dna prepriming: a novel approach for prolonged Th1-biased immunity","volume":"198","author":"Kobayashi","year":"1999","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2022.102172","article-title":"Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics","volume":"70","author":"Kaur","year":"2022","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib21","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/14760584.2015.966085","article-title":"Vaccine adjuvant uses of poly-IC and derivatives","volume":"14","author":"Martins","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.bioactmat.2024.12.029_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1043109","article-title":"New-age vaccine adjuvants, their development, and future perspective","volume":"14","author":"Verma","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00733-16","article-title":"Listeria monocytogenes-induced cell death inhibits the generation of cell-mediated immunity","volume":"85","author":"Theisen","year":"2017","journal-title":"Infect. Immun."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib24","doi-asserted-by":"crossref","first-page":"12419","DOI":"10.1073\/pnas.1019041108","article-title":"Listeria monocytogenes engineered to activate the Nlrc4 inflammasome are severely attenuated and are poor inducers of protective immunity","volume":"108","author":"Sauer","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.923477","article-title":"Effects of helicobacter pylori on tumor microenvironment and immunotherapy responses","volume":"13","author":"Deng","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019614","article-title":"Induction of TLR-2 and TLR-5 expression by Helicobacter pylori switches cagPAI-dependent signalling leading to the secretion of IL-8 and TNF-\u03b1","volume":"6","author":"Kumar Pachathundikandi","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bioactmat.2024.12.029_bib27","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41577-022-00707-2","article-title":"A guide to antigen processing and presentation","volume":"22","author":"Pishesha","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11020176","article-title":"Releasing the immune system brakes using siRNAs enhances cancer immunotherapy","volume":"11","author":"Sioud","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.bioactmat.2024.12.029_bib29","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nri.2017.26","article-title":"BACH transcription factors in innate and adaptive immunity","volume":"17","author":"Igarashi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib30","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1038\/nbt1035","article-title":"Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity","volume":"22","author":"Shen","year":"2004","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib31","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nri2093","article-title":"SOCS proteins, cytokine signalling and immune regulation","volume":"7","author":"Yoshimura","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2012.00020","article-title":"SOCS, inflammation, and autoimmunity","volume":"3","author":"Yoshimura","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib33","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12026-014-8562-8","article-title":"Silenced suppressor of cytokine signaling 1 (SOCS1) enhances the maturation and antifungal immunity of dendritic cells in response to Candida albicans in vitro","volume":"61","author":"Shi","year":"2015","journal-title":"Immunol. Res."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib34","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98368","article-title":"Efficacy of intracellular immune checkpoint-silenced DC vaccine","volume":"3","author":"Wang","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.bioactmat.2024.12.029_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13101621","article-title":"Functionalizing ferritin nanoparticles for vaccine development","volume":"13","author":"Rodrigues","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioactmat.2024.12.029_bib36","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature12202","article-title":"Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies","volume":"499","author":"Kanekiyo","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.bioactmat.2024.12.029_bib37","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.cell.2015.07.043","article-title":"Rational design of an epstein-barr virus vaccine targeting the receptor-binding site","volume":"162","author":"Kanekiyo","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.bioactmat.2024.12.029_bib38","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41565-020-0648-y","article-title":"Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B","volume":"15","author":"Wang","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf1591","article-title":"Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates","volume":"7","author":"He","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1021\/acscentsci.0c01405","article-title":"A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice","volume":"7","author":"Powell","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106974","article-title":"L-ferritin binding to scara5: a new iron traffic pathway potentially implicated in retinopathy","volume":"9","author":"Mendes-Jorge","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bioactmat.2024.12.029_bib42","doi-asserted-by":"crossref","first-page":"15727","DOI":"10.1074\/jbc.RA120.014690","article-title":"Interactions of ferritin with scavenger receptor class A members","volume":"295","author":"Yu","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib43","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1016\/j.vaccine.2021.07.021","article-title":"Immunogenicity study of engineered ferritins with C- and N-terminus insertion of Epstein-Barr nuclear antigen 1 epitope","volume":"39","author":"Qu","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.bioactmat.2024.12.029_bib44","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1021\/bi9618474","article-title":"Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers","volume":"36","author":"Wyman","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.bioactmat.2024.12.029_bib45","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1016\/j.xphs.2017.05.014","article-title":"Identification and evaluation of the minimum unit of a KALA peptide required for gene delivery and immune activation","volume":"106","author":"Miura","year":"2017","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib46","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib47","doi-asserted-by":"crossref","first-page":"10159","DOI":"10.1073\/pnas.0812414106","article-title":"Physicochemical principles that regulate the competition between functional and dysfunctional association of proteins","volume":"106","author":"Pechmann","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib48","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/elsc.201700058","article-title":"Influence of the production system on the surface properties of influenza A virus particles","volume":"17","author":"H\u00e4mmerling","year":"2017","journal-title":"Eng. Life Sci."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib49","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s00262-022-03144-1","article-title":"Interleukin-12 as an in situ cancer vaccine component: a review","volume":"71","author":"Cheng","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib50","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00281-019-00744-5","article-title":"CD8+ T cell exhaustion","volume":"41","author":"Kurachi","year":"2019","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib51","article-title":"Turning the old adjuvant from gel to nanoparticles to amplify CD8+ T cell responses","volume":"5","author":"Jiang","year":"2018","journal-title":"Adv. Sci."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib52","doi-asserted-by":"crossref","first-page":"5968","DOI":"10.3390\/cancers13235968","article-title":"Gp-100 as a novel therapeutic target in uveal melanoma","volume":"13","author":"Martinez-Perez","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bioactmat.2024.12.029_bib53","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1056\/NEJMc1107536","article-title":"gp100 peptide vaccine in melanoma","volume":"365","author":"Minor","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib54","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.bioactmat.2024.12.029_bib55","doi-asserted-by":"crossref","DOI":"10.1002\/anbr.202200122","article-title":"Application of nanotechnology in therapeutic cancer vaccines","volume":"3","author":"Guo","year":"2023","journal-title":"Adv NanoBiomed Res"},{"key":"10.1016\/j.bioactmat.2024.12.029_bib56","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","article-title":"Cancer vaccines: the next immunotherapy frontier","volume":"3","author":"Lin","year":"2022","journal-title":"Nat. Can. (Ott.)"},{"key":"10.1016\/j.bioactmat.2024.12.029_bib57","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1126\/science.aar7112","article-title":"Personalized vaccines for cancer immunotherapy","volume":"359","author":"Sahin","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.bioactmat.2024.12.029_bib58","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrd.2018.85","article-title":"Personalized cancer vaccines hit the spot","volume":"17","author":"Cully","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib59","doi-asserted-by":"crossref","first-page":"v496","DOI":"10.1093\/annonc\/mdz253.040","article-title":"1214P - randomized phase II clinical trial of NY-ESO-1 protein vaccine combined with cholesteryl pullulan (CHP-NY-ESO-1) in resected esophageal cancer patients","volume":"30","author":"Kageyama","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib60","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10588","article-title":"Cancer vaccines in the clinic","volume":"9","author":"Janes","year":"2024","journal-title":"Bioeng Transl Med"},{"key":"10.1016\/j.bioactmat.2024.12.029_bib61","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3390\/vaccines9050509","article-title":"Stay on target: reengaging cancer vaccines in combination immunotherapy","volume":"9","author":"Wolfson","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.bioactmat.2024.12.029_bib62","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx245","article-title":"Personalized cancer vaccines advance in the clinic","volume":"109","author":"Schmidt","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113914","article-title":"Vaccine delivery systems toward lymph nodes","volume":"179","author":"Ding","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib64","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3390\/v16010120","article-title":"mRNA vaccine nanoplatforms and innate immunity","volume":"16","author":"Wei","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.bioactmat.2024.12.029_bib65","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1007\/s00262-018-2158-4","article-title":"Personalized cancer vaccines: adjuvants are important, too","volume":"67","author":"Gouttefangeas","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib66","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aas9103","article-title":"TCR signal strength controls the differentiation of CD4+ effector and memory T cells","volume":"3","author":"Snook","year":"2018","journal-title":"Sci Immunol"},{"key":"10.1016\/j.bioactmat.2024.12.029_bib67","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.4049\/jimmunol.1901167","article-title":"TCR signal strength and antigen affinity regulate CD8+ memory T cells","volume":"205","author":"Solouki","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.642583","article-title":"Deciphering human leukocyte antigen susceptibility maps from immunopeptidomics characterization in oncology and infections","volume":"11","author":"Juanes-Velasco","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib69","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s10194-021-01324-5","article-title":"Delayed headache after COVID-19 vaccination: a red flag for vaccine induced cerebral venous thrombosis","volume":"22","author":"Garc\u00eda-Azor\u00edn","year":"2021","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.bioactmat.2024.12.029_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.782335","article-title":"Potential anionic substances binding to platelet factor 4 in vaccine-induced thrombotic thrombocytopenia of ChAdOx1-S vaccine for SARS-CoV-2","volume":"12","author":"Pang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110143","article-title":"SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity","volume":"37","author":"Joyce","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib72","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abi5735","article-title":"A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates","volume":"14","author":"Joyce","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioactmat.2024.12.029_bib73","doi-asserted-by":"crossref","first-page":"e581","DOI":"10.1016\/S2666-5247(23)00410-X","article-title":"SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial","volume":"5","author":"Ober Shepherd","year":"2024","journal-title":"The Lancet Microbe"},{"key":"10.1016\/j.bioactmat.2024.12.029_bib74","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/em.22566","article-title":"Unbiased whole genome detection of ultrarare off-target mutations in genome-edited cell populations by HiFi sequencing","volume":"64","author":"Miranda","year":"2023","journal-title":"Environ. Mol. Mutagen."}],"container-title":["Bioactive Materials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452199X24005668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452199X24005668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T05:09:56Z","timestamp":1741151396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452199X24005668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":74,"alternative-id":["S2452199X24005668"],"URL":"https:\/\/doi.org\/10.1016\/j.bioactmat.2024.12.029","relation":{},"ISSN":["2452-199X"],"issn-type":[{"value":"2452-199X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer vaccine designed from homologous ferritin-based fusion protein with enhanced DC-T cell crosstalk for durable adaptive immunity against tumors","name":"articletitle","label":"Article Title"},{"value":"Bioactive Materials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioactmat.2024.12.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by KeAi Communications Co., Ltd.","name":"copyright","label":"Copyright"}]}}